Department of Orthopedics, Banner Health, 13995 W Statler Blvd #200, Surprise, Phoenix, AZ, 85374, USA.
Department of Orthopedics, University of Pittsburg Medical Center (UPMC) Harrisburg, Harrisburg, PA, USA.
Eur Spine J. 2023 Oct;32(10):3651-3658. doi: 10.1007/s00586-023-07859-2. Epub 2023 Aug 8.
To delineate whether use of a PTH analogue in the 1-year peri-operative period improves lumbar bone density.
A prospectively collected data registry of 254 patients who underwent CMIS correction of ASD (Cobb angle > 20 or SVA > 50 mm or (PI-LL) > 10) from Jan 2011 to Jan 2020 was analysed. Patients who were placed on PTH analogues for one year in conjunction with surgery were included in the study. Ultimately, 41 patients who had pre- and two-year post-operative CT scans for review were included in this study. Hounsfield units were measured off of the L1-L3 levels for all patients before and after surgery on pre-op and post-op CT scans.
The mean age of patients in this study was 70 (52-84, SD 7). Mean follow-up was 66 (24-132, SD 33) months. Twenty-three patients met criteria for severe deformity (Cobb angle > 50 degrees or SVA > 95 mm or PI/LL mismatch > 20 or PT > 30). Based off 2-year post-op CT scan, there were significant improvements in L1 Hounsfield units when comparing pre-op values (96; SD 55) to post-op values (185 SD 102); p. < 0.05. There was no screw loosening or screw pull out. There were 2 patients with PJF (4.8%). Both these patients had not completed their PTH treatment: one only took PTH for 3 months (PJF at 2-year post-op) and the other one took it only for 1 month (PJF at 1-year post-op). No increase in bone density was noted (based off of Hounsfield units) in five patients (12%) despite completion of their PTH therapy. Only one patient experienced nausea from PTH therapy. There were no other PTH related adverse events.
The incidence of PTH analogues failing to increase bone density in our series was low at 12%. This study shows that PTH analogues may be a powerful adjunct for increasing bone density and may help to mitigate the risk of mechanical complications in patients undergoing deformity correction with minimally invasive techniques. Future comparative studies are warranted to confirm these latter findings and to potentially protocolize the ideal peri-operative bone health optimization strategy.
阐述围手术期使用甲状旁腺激素类似物是否能提高腰椎骨密度。
对 2011 年 1 月至 2020 年 1 月期间接受 CMIS 矫正 ASD(Cobb 角>20°或 SVA>50mm 或(PI-LL)>10)的 254 例患者的前瞻性数据进行了分析。在这项研究中,将在手术期间同时使用甲状旁腺激素类似物治疗一年的患者纳入研究。最终,共有 41 例患者术前和术后两年的 CT 扫描可供回顾,这些患者纳入本研究。所有患者在术前和术后 CT 扫描上测量 L1-L3 水平的 Hounsfield 单位。
本研究患者的平均年龄为 70 岁(52-84 岁,SD 7)。平均随访时间为 66 个月(24-132 个月,SD 33 个月)。23 例患者符合严重畸形标准(Cobb 角>50°或 SVA>95mm 或 PI/LL 不匹配>20 或 PT>30)。根据术后 2 年的 CT 扫描,与术前值(96;SD 55)相比,术后值(185;SD 102)有显著改善,p<0.05。没有螺钉松动或螺钉拔出。有 2 例发生了胸腰椎后凸畸形(PJFs)(4.8%)。这 2 例患者均未完成甲状旁腺激素治疗:1 例仅接受了 3 个月的治疗(术后 2 年发生 PJF),另 1 例仅接受了 1 个月的治疗(术后 1 年发生 PJF)。尽管完成了甲状旁腺激素治疗,但仍有 5 例患者(12%)的骨密度未见增加(基于 Hounsfield 单位)。只有 1 例患者出现甲状旁腺激素治疗相关的恶心。没有其他甲状旁腺激素相关的不良反应。
在我们的研究中,甲状旁腺激素类似物未能增加骨密度的发生率较低,为 12%。本研究表明,甲状旁腺激素类似物可能是增加骨密度的有力辅助手段,并有助于降低微创技术矫正畸形患者发生机械并发症的风险。需要进一步的前瞻性比较研究来证实这些发现,并可能制定理想的围手术期骨骼健康优化策略。